Scorpion Nabs $108m, Biopharma Veterans For Precision Oncology 2.0
Serial Entrepreneur Gary Glick Previously Founded IFM, Lycera, FirstWave
Executive Summary
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
You may also be interested in...
Finance Watch: Scorpion Closes $162m Series B, Bringing Recent Total To $270m
Private Company Edition: The pre-J.P. Morgan Healthcare Conference financing news deluge during the first week of 2021 included several significant venture capital deals, including a $226m series B round for Affinivax, Ikena’s $120m series B round and an $88m series A round for Aro.
Three IPOs, Three SPAC Mergers, But One Company Opted Out
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.
ICER Suggests Price Of $2,500-$8,300 For Biogen’s Aducanumab
Given mixed Phase III results for the Alzheimer’s drug and potentially severe side effects for the once-monthly infused therapy, ICER’s recommendation came in below analyst expectations.